As of 2025-11-18, the EV/EBITDA ratio of Oxford BioMedica PLC (OXB.L) is -175.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OXB.L's latest enterprise value is 830.57 mil GBP. OXB.L's TTM EBITDA according to its financial statements is -4.72 mil GBP. Dividing these 2 quantities gives us the above OXB.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.7x - 9.9x | 7.5x |
| Forward P/E multiples | 6.0x - 10.4x | 8.2x |
| Fair Price | (62.61) - (77.23) | (69.62) |
| Upside | -110.2% - -112.6% | -111.4% |
| Date | EV/EBITDA |
| 2025-11-14 | -171.81 |
| 2025-11-13 | -176.13 |
| 2025-11-12 | -176.13 |
| 2025-11-11 | -177.47 |
| 2025-11-10 | -176.66 |
| 2025-11-07 | -180.98 |
| 2025-11-06 | -182.86 |
| 2025-11-05 | -188.79 |
| 2025-11-04 | -194.18 |
| 2025-11-03 | -186.37 |
| 2025-10-31 | -188.93 |
| 2025-10-30 | -187.98 |
| 2025-10-29 | -187.45 |
| 2025-10-28 | -183.94 |
| 2025-10-27 | -177.74 |
| 2025-10-24 | -175.05 |
| 2025-10-23 | -172.35 |
| 2025-10-22 | -166.15 |
| 2025-10-21 | -165.88 |
| 2025-10-20 | -166.15 |
| 2025-10-17 | -169.39 |
| 2025-10-16 | -177.47 |
| 2025-10-15 | -176.13 |
| 2025-10-14 | -178.82 |
| 2025-10-13 | -185.56 |
| 2025-10-10 | -184.48 |
| 2025-10-09 | -185.83 |
| 2025-10-08 | -185.56 |
| 2025-10-07 | -178.82 |
| 2025-10-06 | -180.71 |
| 2025-10-03 | -176.66 |
| 2025-10-02 | -170.47 |
| 2025-10-01 | -170.20 |
| 2025-09-30 | -161.84 |
| 2025-09-29 | -161.30 |
| 2025-09-26 | -156.72 |
| 2025-09-25 | -166.69 |
| 2025-09-24 | -168.31 |
| 2025-09-23 | -169.66 |
| 2025-09-22 | -180.44 |
| 2025-09-19 | -168.85 |
| 2025-09-18 | -166.42 |
| 2025-09-17 | -169.39 |
| 2025-09-16 | -168.58 |
| 2025-09-15 | -171.81 |
| 2025-09-12 | -166.69 |
| 2025-09-11 | -173.43 |
| 2025-09-10 | -173.97 |
| 2025-09-09 | -171.27 |
| 2025-09-08 | -169.66 |